应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
07630 英派药业-B
待上市 05-06 16:00:00
0.000
+0.000
--
最高
0.000
最低
0.000
成交量
0.00
今开
0.000
昨收
0.000
日振幅
0.00%
总市值
0.00
流通市值
0.00
总股本
2.34亿
成交额
0.00
换手率
0.00%
流通股本
2.34亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
“港股合成致死肿瘤药第一股”英派药业启动招股，明星基石加持，拟5月13日上市
同壁财经 · 15:27
“港股合成致死肿瘤药第一股”英派药业启动招股，明星基石加持，拟5月13日上市
即将亮相：港股合成致死肿瘤药第一股英派药业
医药投资部落 · 15:25
即将亮相：港股合成致死肿瘤药第一股英派药业
港股18A再迎明星biotech，英派药业招股开始，合成致死稀缺标的获豪华基石认购
信阳新闻网 · 05-05 19:43
港股18A再迎明星biotech，英派药业招股开始，合成致死稀缺标的获豪华基石认购
英派药业开启招股：拟募资9亿港元 5月13日上市 腾讯与药明康德加持
雷递网 · 05-05 13:19
英派药业开启招股：拟募资9亿港元 5月13日上市 腾讯与药明康德加持
IMPACT Therapeutics（南京英派药业）拟全球发售：最高发售价21.75港元，合共发行约4,197,900股香港公开发售股份
公告速递 · 05-05 06:27
IMPACT Therapeutics（南京英派药业）拟全球发售：最高发售价21.75港元，合共发行约4,197,900股香港公开发售股份
礼来3亿美金收购临床前阶段下一代双载荷ADC平台，英派药业同赛道布局
药融圈 · 04-30
礼来3亿美金收购临床前阶段下一代双载荷ADC平台，英派药业同赛道布局
合成致死2.0：PARP之后，谁是下一个百亿靶点？
研发客 · 04-30
合成致死2.0：PARP之后，谁是下一个百亿靶点？
加载更多
公司概况
公司名称：
英派药业-B
所属市场：
SEHK
上市日期：
--
主营业务：
英派药业致力于研发具有自主知识产权的靶向抗癌创新药,专注于合成致死作用机制。公司以DNA损伤修复通路(DDR)自主研发产品为基础,构建了全球生物医药公司中覆盖面最广的DDR产品管线之一,并且正在逐步拓展到更多的全新的合成致死靶点。 公司管线包括PARP抑制剂塞纳帕利(Senaparib/IMP4297)、Wee1抑制剂(IMP7068)、ATR抑制剂(IMP9064)、PARP1选择性抑制剂(IMP1734,与美国Eikon Therapeutics合作开发)以及多个其他DDR靶点抑制剂。其中最成熟的研发项目PARP抑制剂塞纳帕利在全球范围包含中国已开展卵巢癌、小细胞肺癌等适应症的临床II/III期研究。塞纳帕利用于晚期卵巢癌全人群一线维持治疗的III期临床研究(FLAMES)已达到主要研究终点,显示了同类最佳的药效和安全性。基于FLAMES研究成果,中国国家药监局(NMPA)已于2025年1月批准了塞纳帕利的新药上市申请。Wee1抑制剂IMP7068和ATR抑制剂IMP9064已在包括美国、中国在内的全球多个国家及地区开展I期临床研究,确定了临床II期推荐剂量(RP2D)。PARP1选择性抑制剂IMP1734已经获得FDA和NMPA的临床试验许可,在2024年初完成第一例患者入组。
发行价格：
--
{"stockData":{"symbol":"07630","market":"HK","secType":"STK","nameCN":"英派药业-B","latestPrice":0,"timestamp":1778054400000,"preClose":0,"halted":7,"volume":0,"delay":0,"floatShares":234000000,"shares":234000000,"eps":0,"marketStatus":"待上市","change":0,"latestTime":"05-06 16:00:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778635800000},"marketStatusCode":8,"adr":0,"listingDate":1778601600000,"exchange":"SEHK","adjPreClose":0,"openAndCloseTimeList":[[1778031000000,1778040000000],[1778043600000,1778054400000]],"volumeRatio":0,"ipoDetail":{"name":"英派药业－Ｂ","exchange":"SEHK","listingDate":"2026-05-13","sharesOutstanding":276165130,"sharesFloat":276165130,"offerAmount":41977000,"priceRange":"19.750 - 21.750","market":"HK","openProspectusDate":"2026-05-05","openProspectusUrl":"https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0505/2026050500024_c.pdf","purchaseBeginDate":"2026-05-05","purchaseEndDate":"2026-05-08","winningDate":"2026-05-12","currency":"HKD","minPurchaseQuantity":200,"peRate":-17.52,"use":"1、约51%或398.37百万港元将用于为核心产品塞纳帕利正在进行及计划中的临床开发、监管批准以及商业化提供资金；\n2、约31%或242.15百万港元将用于为关键产品IMP1734及IMP9064正在进行的临床开发提供资金；\n3、约8%或62.49百万港元将用于为其他管线资产、IMP1707、IMP7068、IMP22、IMP25、IMP08、IMP13及IMP10的研发活动提供资金；\n4、约8%或62.49百万港元将用于为研发平台的开发及扩大药物管线提供资金；\n5、约2%或15.62百万港元将用于营运资金及其他一般公司用途。","industryId":"204005","industryName":"医疗保健","business":"公司是一家处于商业化阶段的创新驱动型生物技术公司，致力于在全球范围内推进基于合成致死(synthetic lethality)机制的精准抗癌疗法，打造创新疗法，以满足癌症患者未被满足的医疗需求。公司自主研发的核心产品塞纳帕利已在中国获批上市，作为卵巢癌一线维持疗法，适用于全人群（无论突变状态），并展现出令人信服的临床特征。通过整合小分子药物与新兴疗法（包括新型抗体偶联药物和蛋白降解剂）的自主研发平台，公司持续推动创新突破。","subscribed":65.39,"marketCap":5454000000,"minimumCapital":4393.88,"overAllotment":true,"lotSize":200,"issueOpenRate":0.1,"subscribeGear":"200,400,600,800,1000,1200,1400,1600,1800,2000,3000,4000,5000,6000,7000,8000,9000,10000,20000,30000,40000,50000,60000,70000,80000,90000,100000,200000,300000,400000,500000,600000,700000,800000,900000,1000000,1250000,1500000,1750000,2098800","issueRatio":0.1,"offeringMechanism":"B"},"greyMarketDetail":{"greyDate":"2026-05-12","greyDateTimestamp":1778515200000,"greyOpeningTime":1778573700000,"greyClosingTime":1778581800000,"showGreyQuote":false,"openProspectusDate":"2026-05-05","listingDate":"2026-05-13"},"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/07630","defaultTab":"news","newsList":[{"id":"1114924651","title":"“港股合成致死肿瘤药第一股”英派药业启动招股，明星基石加持，拟5月13日上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1114924651","media":"同壁财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114924651?lang=zh_cn&edition=full","pubTime":"2026-05-06 15:27","pubTimestamp":1778052443,"startTime":"0","endTime":"0","summary":"据消息，南京英派药业股份有限公司于2026年5月5日至8日开启招股， 公司拟全球发售约4198万股H股，每股发售价最高至21.75港元，募资规模最高超9亿港元。公司预计将于2026年5月13日在港股主板上市。其中，IMP32是全球首个、且目前唯一靶向CEACAM5的TOP1i+ATRi双载荷ADC，凭借明确的合成致死协同效应，已成为全球巨头战略布局的核心方向。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://tongbicapital.com/news?id=1116351&feClassCode=hsag","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"lsy1668077363049","symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123297572","title":"即将亮相：港股合成致死肿瘤药第一股英派药业","url":"https://stock-news.laohu8.com/highlight/detail?id=1123297572","media":"医药投资部落","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123297572?lang=zh_cn&edition=full","pubTime":"2026-05-06 15:25","pubTimestamp":1778052358,"startTime":"0","endTime":"0","summary":"汇聚了中国创新药行业核心资产的港股18A板块，即将迎来又一家创新药细分赛道的龙头企业：有着“合成致死肿瘤药第一股”之称的英派药业，已在5月5日开启港股招股流程，预计5月13日于香港联交所主板挂牌上市。新技术赛道扩展市场往往习惯将英派药业定位为一家深度绑定合成致死赛道的小分子药物公司，这一判断并不全面。这意味着，英派药业的技术半径正从合成致死小分子药物赛道，延伸到围绕肿瘤治疗的多种前沿技术路线。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://mp.weixin.qq.com/s/IRYuOSKv3y13KkTaFyQC4A?from=groupmessage&scene=1&subscene=10000&sessionid=1778048506&clicktime=1778050535&enterid=1778050535&ascene=1&fasttmpl_type=0&fasttmpl_fullversion=8237539-zh_CN-zip&fasttmpl_flag=0&realreporttime=1778050535337","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"lsy1629166856219","symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633092917","title":"港股18A再迎明星biotech，英派药业招股开始，合成致死稀缺标的获豪华基石认购","url":"https://stock-news.laohu8.com/highlight/detail?id=2633092917","media":"信阳新闻网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633092917?lang=zh_cn&edition=full","pubTime":"2026-05-05 19:43","pubTimestamp":1777981409,"startTime":"0","endTime":"0","summary":"2026年5月5日，南京英派药业股份有限公司（简称“英派药业”，股票代码:07630.HK）开启招股，拟全球发售约4198万股H股(视乎发售量调整权及超额配股权行使与否而定)，其中中国香港发售股份约420万股，国际发售股份约3778万股；2026年5月5日至5月8日招股，每股发售价格最高至21.75港元，每手买卖单位为200股，募集资金规模最高超9亿港元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.p5w.net/roll/finance/202605/t20260505_6469559.htm","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"lsy1778052843920","symbols":["07630","BK4087","BK4588","VXUS","BK4585","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633991639","title":"英派药业开启招股：拟募资9亿港元 5月13日上市 腾讯与药明康德加持","url":"https://stock-news.laohu8.com/highlight/detail?id=2633991639","media":"雷递网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633991639?lang=zh_cn&edition=full","pubTime":"2026-05-05 13:19","pubTimestamp":1777958392,"startTime":"0","endTime":"0","summary":"南京英派药业股份有限公司（简称：“英派药业”，股票代码：“07630”）日前开启招股，准备2026年5月13日在港交所上市。","market":"hk","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260505/6391358397744973652167989.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260505/6391358397744973652167989.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n33544/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["LU0823397285.USD","LU1235295612.USD","LU2462611646.USD","LU1044874839.SGD","LU1733274390.USD","LU0203345920.USD","LU1733274473.HKD","BK1615","LU0348816934.USD","IE00B031HY20.USD","LU1439103000.SGD","LU1691799644.USD","LU1105468828.SGD","LU0608807433.USD","SG9999001226.SGD","LU0128522744.USD","HK0000320264.USD","LU1328615791.USD","LU0886674414.USD","LU0039217434.USD","LU0572944931.SGD","LU1316542783.SGD","SG9999014914.USD","LU1969619763.USD","LU0051755006.USD","LU1831875114.USD","LU0878004406.USD","BK1609","LU0831103253.SGD","LU0708995583.HKD","LU0348783233.USD","LU1224444064.USD","LU1282649810.SGD","LU0873338254.USD","SG9999015945.SGD","LU0543330566.HKD","LU1814569148.SGD","LU0823038988.USD","LU2476274720.SGD","BK1517","IE00B543WZ88.USD","LU0173614495.USD","SG9999013353.USD","LU0650527681.SGD","LU0049112450.USD","LU1226288170.HKD","IE00BZ08YR35.GBP","LU0345776255.USD","BK1610","LU0054450605.USD","IE0003851619.USD","LU0588545490.SGD","HK0000306685.HKD","LU0672654166.SGD","LU2257852520.SGD","SG9999000418.SGD","LU1629966141.USD","LU0043850808.USD","LU0588545904.SGD","LU0642271901.SGD","LU1804176565.USD","LU0244354667.USD","SG9999015978.USD","LU0143863198.USD","LU0149534421.HKD","HTCD.SI","LU0890818403.SGD","LU1769817179.HKD","LU0516423091.SGD","LU0588546209.SGD","BK4588","LU0828238088.HKD","IE00B5MMRT66.SGD","LU1979443071.USD","LU0210533765.USD","SG9999001069.SGD","IE00B067MR52.USD","LU2778985437.USD","IE0003795394.USD","LU2226246903.HKD","LU1868837722.USD","LU2476274308.USD","LU0048580855.USD","LU1719994722.HKD","LU1196710351.USD","LU1974910355.USD","LU1961090484.USD","SG9999007991.SGD","BK4077","LU0985320562.USD","LU1688375341.USD","SG9999001093.SGD","LU0648948544.HKD","IE00B0JY6N72.USD","BK1526","LU0417516738.SGD","LU0261950983.USD","LU0823426308.USD","LU2237443978.SGD","LU0431992006.USD","LU2039709279.SGD","LU0823413587.USD","LU0164865239.USD","LU0328353924.USD","IE0031814852.USD","HK0000320223.HKD","LU0048388663.USD","LU0516422440.USD","BK1516","LU0052750758.USD","LU0417516902.SGD","LU0359201612.USD","LU2362540622.SGD","LU2362541273.HKD","BK4581","LU1226288097.SGD","LU0828237510.HKD","LU1813983027.USD","LU2251237488.HKD","LU0210526637.USD","SGXZ31699556.SGD","LU2148510915.USD","LU0882747503.HKD","LU0456846285.SGD","LU0786609619.USD","LU0918141705.HKD","LU1152091168.USD","LU0561508036.HKD","LU2133065610.SGD","LU1064130708.USD","LU0823041008.USD","LU0823413660.USD","LU0543330483.HKD","BK1095","LU0880133367.SGD","LU1046422090.SGD","LU0254981946.USD","LU1226287792.SGD","LU0175139822.USD","LU0572939691.SGD","HK0000306701.USD","HK0000914686.HKD","LU0823040885.USD","LU0414403682.SGD","IE00B29SXG58.USD","LU0070217475.USD","LU1807302812.USD","IE00BPRC5H50.USD","LU0456827905.SGD","LU0048597586.USD","LU0181495838.USD","LU0348783662.USD","LU0456842615.SGD","LU2097828631.EUR","LU1226288253.USD","LU0607220059.USD","LU0972618739.USD","SG9999002828.SGD","LU2097828714.EUR","LU1675838814.USD","IE00B031J352.USD","LU0348723411.USD","LU0797268264.HKD","LU0577902454.USD","SG9999015986.USD","LU1102505762.USD","LU0348766576.USD","IE00B8HQ1Z84.USD","IE00B3M56506.USD","IE0009570106.USD","LU0828237940.HKD","LU0029874905.USD","LU0651947912.USD","LU1568876251.USD","BK1586","LU0259732245.USD","SGXZ81514606.USD","LU0488056044.USD","LU0348788117.USD","LU0611395673.USD","LU2106854487.HKD","LU0329678337.USD","LU0047713382.USD","LU1224709979.USD","LU2399975544.HKD","SG9999001051.SGD","TCEHY","LU2237443622.USD","IE00BQXX3F31.USD","LU0106252389.USD","LU0871576103.HKD","LU0192582467.USD","LU0348735423.USD","LU0463099449.HKD","LU2125910500.SGD","LU0540923850.HKD","LU0228659784.USD","LU1568876335.HKD","LU1044875133.USD","LU0231483743.USD","SG9999003461.SGD","LU0589944569.HKD","BK4585","SGXZ90724238.SGD","LU2097828557.USD","LU2023250504.SGD","LU2498475776.HKD","BK1589","LU0633140727.USD","LU0128522157.USD","LU1226287875.USD","LU2247934214.USD","LU2097828805.USD","LU0314109678.HKD","LU2293587155.HKD","LU1770034418.SGD","LU0738912210.USD","LU1917777945.USD","LU0868486357.SGD","SG9999002562.SGD","IE00BQXX3C00.GBP","LU0594300179.USD","LU1282651048.USD","LU1655091459.SGD","LU2279701549.SGD","LU0096374516.USD","LU0329678170.USD","LU0149721374.USD","LU0164880469.USD","LU2045819591.USD","LU0675040207.SGD","LU0235996351.USD","LU1064131003.USD","LU0293314216.USD","LU0251144936.SGD","LU0651946864.USD","LU0359202008.SGD","LU0140636845.USD","LU0502904849.HKD","LU0348827113.USD","BK1502","LU1439102457.SGD","LU0541502299.USD","LU0289960550.SGD","LU2177674079.SGD","LU0384037296.USD","SG9999001846.SGD","IE00B031HW06.USD","LU1303224171.USD","LU1196710864.SGD","LU0326950275.SGD","LU0326948709.USD","LU1196710195.USD","LU0169518387.USD","LU1718418525.SGD","LU0784639295.USD","LU2362541513.USD","LU2087589342.USD","SG9999015952.SGD","LU0117841782.USD","TCHmain","LU1997245177.USD","LU0862451837.USD","LU1808992512.USD","LU1251922891.USD","LU0708995153.HKD","LU1794554557.SGD","LU0229945570.USD","LU1960683339.HKD","LU1880383440.USD","LU0106259558.USD","LU1242518931.SGD","BK1531","LU0348825331.USD","LU0287142896.SGD","SGXZ51526630.SGD","LU0541501648.USD","LU2097828474.EUR","LU2237443382.USD","LU0261947096.USD","LU0210527791.USD","LU0499858602.USD","LU2242644610.SGD","LU1725190679.HKD","LU0320764243.SGD","LU1934453819.USD","LU0417516571.SGD","GB00BDT5M118.USD","LU0072913022.USD","IE0008368742.USD","LU1282649141.HKD","BK1608","LU1997245094.SGD","LU2488822045.USD","LU0315179316.USD","LU1211504680.USD","LU0165289439.USD","LU1044876610.USD","SG9999014674.SGD","LU0516423174.USD","LU0516422952.EUR","LU1770036033.HKD","SG9999000459.SGD","LU1956131251.USD","LU1048484197.HKD","LU1048596156.SGD","SG9999014906.USD","BK4550","LU1810669033.SGD","LU2237443549.SGD","LU1504937902.USD","LU0345775950.USD","LU2237443465.HKD","LU1515016050.SGD","IE00BQXX3D17.EUR","LU1366334651.USD","LU0737861772.HKD","LU0683595622.HKD","LU0918141887.USD","LU1769817096.USD","LU0577902538.SGD","LU0979878070.USD","LU1226287529.USD","IE00BGV7N243.SGD","LU0345769631.USD","LU3063872942.SGD","00700","BK1618","BK4504","LU0029875118.USD","LU0469268626.HKD","LU0862451753.SGD","LU2317271919.USD","LU2449936058.SGD","LU1023057109.AUD","LU1868838027.USD","LU1242518857.USD","HK0001040143.USD","LU0819123356.HKD","LU0163747925.USD","LU0516422366.SGD","LU2237443895.HKD","LU0107464264.USD","LU0196878994.USD","LU0531970944.HKD","LU0143863784.USD","LU1282648689.USD","LU0264606111.USD","LU0898667661.SGD","LU0061477393.USD","SG9999018857.SGD","LU1993786604.SGD","LU1997244956.HKD","LU1981816686.USD","LU0819121731.USD","LU0633140560.USD","LU2328871848.SGD","LU0327786744.USD","LU0605514214.HKD","BK1141","SGXZ99366536.SGD","LU0577902611.USD","LU0531971595.HKD","BK0216","LU0320764755.SGD","LU1880383366.USD","LU0132412106.USD","LU1328277881.USD","SG9999006514.SGD","LU0211977185.USD","IE0001KFT4U8.USD","LU0359201885.HKD","LU0054237671.USD","IE0032431581.USD","LU1102505929.USD","SG9999018865.SGD","SG9999014880.SGD","HK0001040168.HKD","LU0348805143.USD","LU0049853897.USD","LU0509642566.USD","SG9999000327.SGD","LU0106959298.USD","LU2051468812.USD","LU0072462343.USD","LU0084288322.USD","LU1282649067.USD","HK0000352291.HKD","LU0501845795.SGD","LU1481107354.HKD","LU1883866441.USD","LU2251237306.USD","LU0593848301.USD","LU0455707207.USD","IE00B0169L03.USD","LU0370786039.SGD","LU0594300419.USD","LU0214875030.USD","LU1720050803.USD","IE00BZ08YS42.EUR","IE00BZ08YT58.USD","LU0878005551.USD","BK1521","LU0080751232.USD","LU0823397103.USD","LU0449509016.USD","LU1051768304.USD","LU0396098781.USD","LU1951186391.HKD","LU0188438112.USD","HK0000914660.USD","BK1576","IE0008368411.USD","LU0307460666.USD","LU0011963245.USD","LU0320764599.SGD","LU1152091754.HKD","IE0034224299.USD","LU1282651121.HKD","LU1642822792.SGD","LU0499858438.USD","LU0588545730.USD","LU1188198961.HKD","IE0003895053.USD","LU0856984785.SGD","LU0127658192.USD","LU2008162690.USD","LU0117844026.USD","LU0823039010.USD","LU0269904917.USD","LU0823426480.USD","SG9999002463.SGD","SG9999017495.SGD","LU0228367735.SGD","LU1323998911.USD","IE0008369823.USD","LU1734074674.USD","IE00BF5LJ272.USD","LU1868837565.USD","LU1785774172.SGD","HK0000352382.USD","LU0441854154.USD","LU0700851271.USD","IE0032834883.USD","LU0345769128.USD","SG9999001689.USD","LU0577902298.EUR","SG9999004220.SGD","LU0634319403.HKD","SG9999014898.SGD","HK0000151867.HKD","LU0067412154.USD","LU0449515922.USD","LU2495084118.USD","LU0821914370.USD","LU0572940350.SGD","LU2125910849.SGD","LU0348767384.USD","LU0211331839.USD","BK1583","LU1048588211.SGD","SG9999006597.SGD","LU0791591158.USD","BK1591","LU2152927971.USD","LU2294711473.HKD","LU0737861699.HKD","LU2265009873.SGD","IE00B8L5B284.USD","SG9999001903.USD","LU1366334578.USD","LU0164872284.USD","LU0608807946.USD","LU1051769294.HKD","LU0348784397.USD","LU0348814723.USD","LU0203347892.USD","LU0577902371.SGD","07630","LU0791590937.USD","LU0865486749.SGD","LU1008478684.HKD","LU0315178854.USD","IE00B97KM107.HKD","IE00B0169N27.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122813661","title":"IMPACT Therapeutics（南京英派药业）拟全球发售：最高发售价21.75港元，合共发行约4,197,900股香港公开发售股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1122813661","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122813661?lang=zh_cn&edition=full","pubTime":"2026-05-05 06:27","pubTimestamp":1777933676,"startTime":"0","endTime":"0","summary":"IMPACT Therapeutics, Inc成立于2009年，专注于基于“合成致死”机制的肿瘤精准治疗药物研发，核心在研产品涵盖PARP1/2抑制剂、ATR抑制剂等，用于多种肿瘤适应症的临床试验。公司在全球布局多条研发管线，核心产品包括IMP4297、IMP1734、IMP9064等，覆盖卵巢癌、乳腺癌、前列腺癌、小细胞肺癌等领域。本次全球发售初步拟发行合共41,977,000股H股，其中4,197,900股用于香港公开发售，余下37,779,200股用于国际发售，另设最高6,296,400股的超额配股权。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"IMPACT Therapeutics（南京英派药业）拟全球发售：最高发售价21.75港元，合共发行约4,197,900股香港公开发售股份","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1154131856","title":"礼来3亿美金收购临床前阶段下一代双载荷ADC平台，英派药业同赛道布局","url":"https://stock-news.laohu8.com/highlight/detail?id=1154131856","media":"药融圈","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154131856?lang=zh_cn&edition=full","pubTime":"2026-04-30 18:53","pubTimestamp":1777546436,"startTime":"0","endTime":"0","summary":"成为全球巨头战略布局的核心方向。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://mp.weixin.qq.com/s/VTcssL2b253Xs-2m2RQC0w","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"lsy1613031030984","symbols":["07630","LLY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160945600","title":"合成致死2.0：PARP之后，谁是下一个百亿靶点？","url":"https://stock-news.laohu8.com/highlight/detail?id=1160945600","media":"研发客","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160945600?lang=zh_cn&edition=full","pubTime":"2026-04-30 18:35","pubTimestamp":1777545344,"startTime":"0","endTime":"0","summary":"后来者如何突围？","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://mp.weixin.qq.com/s/54M7yaODrjrTV0UB9cnrLQ?scene=1&click_id=1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lsy1777545367960","symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"https://www.impacttherapeutics.com/","compareEarnings":[{"period":"1week","weight":0.0085},{"period":"1month","weight":0.0311},{"period":"3month","weight":-0.0353},{"period":"6month","weight":-0.0222},{"period":"1year","weight":0.1508},{"period":"ytd","weight":0.0105}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"英派药业致力于研发具有自主知识产权的靶向抗癌创新药,专注于合成致死作用机制。公司以DNA损伤修复通路(DDR)自主研发产品为基础,构建了全球生物医药公司中覆盖面最广的DDR产品管线之一,并且正在逐步拓展到更多的全新的合成致死靶点。\n公司管线包括PARP抑制剂塞纳帕利(Senaparib/IMP4297)、Wee1抑制剂(IMP7068)、ATR抑制剂(IMP9064)、PARP1选择性抑制剂(IMP1734,与美国Eikon Therapeutics合作开发)以及多个其他DDR靶点抑制剂。其中最成熟的研发项目PARP抑制剂塞纳帕利在全球范围包含中国已开展卵巢癌、小细胞肺癌等适应症的临床II/III期研究。塞纳帕利用于晚期卵巢癌全人群一线维持治疗的III期临床研究(FLAMES)已达到主要研究终点,显示了同类最佳的药效和安全性。基于FLAMES研究成果,中国国家药监局(NMPA)已于2025年1月批准了塞纳帕利的新药上市申请。Wee1抑制剂IMP7068和ATR抑制剂IMP9064已在包括美国、中国在内的全球多个国家及地区开展I期临床研究,确定了临床II期推荐剂量(RP2D)。PARP1选择性抑制剂IMP1734已经获得FDA和NMPA的临床试验许可,在2024年初完成第一例患者入组。","exchange":"SEHK","name":"英派药业-B","nameEN":"IMPACT THERAP-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"英派药业-B(07630)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供英派药业-B(07630)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"英派药业-B,07630,英派药业-B股票,英派药业-B股票老虎,英派药业-B股票老虎国际,英派药业-B行情,英派药业-B股票行情,英派药业-B股价,英派药业-B股市,英派药业-B股票价格,英派药业-B股票交易,英派药业-B股票购买,英派药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"英派药业-B(07630)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供英派药业-B(07630)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}